Background: The goal of mucoactive therapies in cystic fibrosis (CF) is
to enhance sputum clearance and to reduce a progressive decline in lung
function over the patient’s lifetime. We aimed to investigate the level
of consensus among specialists from Italian CF Centers on
appropriateness of therapeutic use of dornase alfa (rhDNase) for CF
patients. Method: A consensus on appropriate prescribing in CF
mucoactive agents was appraised by an online Delphi method, based on a
panel of 27 pulmonologists, coordinated by a Scientific Committee of six
experts in medical care of patients with CF. Results: Full or very high
consensus was reached on several issues related to therapeutic use of
dornase alfa for CF patients in clinical practice. Conclusions: Modified
Delphi method was used to define the most appropriate use of dornase
alfa in routine CF to improve lung function and long-term outcomes in
patients, in agreement with international guidelines on CF management.
Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes
